Nicholas Barber is an Oncology physician affiliated with Washington and Lee University. OpenAlex indexes 102 publications with 3,652 citations (h-index 27); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
875 Oak St SE Ste 4030
Salem, OR 973013984
Telephone
503-561-6444Provider last certified this registry record 30 Jun 2020.
Clinical trials
- Understanding and Appraising the New Medicine Service in England
Sponsor: University of Nottingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20255 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- Amgen Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
54.2%Iron, parenteral preparations54.1%Ferric carboxymaltose100%Part B, office-administered≥27 patientsFactor Xa inhibitor0.1%Eliquis100%Part D≥19 patientsCancer & immunology
17.3%PD-1 inhibitor16.2%Pembrolizumab100%Part B, office-administered≥11 patientsPlatinum-based Drug0.4%Carboplatin100%Part B, office-administered≥13 patients+ 10 more classes in this area
Metabolism & gastrointestinal
17.2%Other antiemetics14.3%Fosaprepitant100%Part B, office-administered≥26 patientsSerotonin-3 Receptor Antagonist2.9%Ondansetron hydrochloride51%Palonosetron hcl48%Ondansetron Odt1%Part D + Part B≥36 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Community recommendations for geochemical data, services and analytical capabilities in the 21st century
Geochimica et Cosmochimica Acta
2023 - Monogenetic volcanoes as windows into transcrustal mush: A case study of Slamet and Loyang volcanoes, Central Java
Journal of Volcanology and Geothermal Research
2023 - Amphibole control on copper systematics in arcs: Insights from the analysis of global datasets
Geochimica et Cosmochimica Acta
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”